Skip to main content

Day: November 14, 2024

HCW Biologics Reports Third Quarter 2024 Financial Results and Business Highlights

Written by Customer Service on . Posted in Earnings Releases And Operating Results.

MIRAMAR, Fla., Nov. 14, 2024 (GLOBE NEWSWIRE) — HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, today reported financial results and recent business highlights for its third quarter ended September 30, 2024.  Dr. Hing C. Wong, Founder and CEO of HCW Biologics, stated, “In the third quarter 2024, the Company expanded our product portfolio and possible disease indications that may be treated with our immunotherapeutic compounds, consisting of compounds constructed using two different platforms. Our expanded portfolio now includes constructs with immune-cell engagers targeting tissue factor and other cell-surface antigens...

Continue reading

QuoteMedia Announces Financial Results for Q3 2024

Written by Customer Service on . Posted in Earnings Releases And Operating Results.

PHOENIX, Nov. 14, 2024 (GLOBE NEWSWIRE) — QuoteMedia, Inc. (OTCQB: QMCI), a leading provider of market data and financial applications, announced financial results for the quarter ended September 30, 2024. QuoteMedia provides banks, brokerage firms, private equity firms, financial planners and sophisticated investors with a more economical, higher quality alternative source of stock market data and related research information. We compete with several larger legacy organizations and a modest community of other smaller companies.  QuoteMedia provides comprehensive market data services, including streaming data feeds, on-demand request-based data (XML/JSON), web content solutions (financial content for website integration) and applications such as Quotestream Professional desktop and mobile.  Highlights for Q3 2024 include the following:Quarterly...

Continue reading

Syntec Optics Holdings, Inc. (Nasdaq: OPTX) Reports Third Quarter 2024 Financial Results

Written by Customer Service on . Posted in Earnings Releases And Operating Results.

Syntec continues sequential revenue growth with positive EBITDA ROCHESTER, NEW YORK, Nov. 14, 2024 (GLOBE NEWSWIRE) — Syntec Optics (Nasdaq: OPTX), a leading provider of mission-critical products to advanced technology defense, biomedical, and communications equipment manufacturers, today reported financial results for the first quarter of 2024. Third Quarter 2024 Financial HighlightsNet Sales of $7.86 million increased by 12.3% from $7.01 million in Q2 2024, and sales from products of $7.33 million increased by 17.2% from $6.26 million in Q3 2023. Adjusted EBITDA decreased to $1.10 million from $1.32 million in Q2 2024. Earnings per Share decreased to $0.00 from $0.01 in Q2 2024.Dean Rudy, CFO, said, “At the previous earnings call, we provided guidance for the third quarter 2024 revenue to be between $9.5 and $11.0 million....

Continue reading

Marker Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates

Written by Customer Service on . Posted in Public Companies.

Marker Therapeutics to receive two grants from NIH Small Business Innovation Research (SBIR) program to support clinical investigation of MT-601 in patients with lymphoma and metastatic pancreatic cancer HOUSTON, Nov. 14, 2024 (GLOBE NEWSWIRE) — Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumors, today reported corporate updates and financial results for the third quarter ended September 30, 2024. “As we approach the end of 2024, we continue to build momentum across our clinical and corporate programs,” said Juan Vera, M.D., President and Chief Executive Officer of Marker Therapeutics. “During the third quarter, we made significant progress in our ongoing Phase 1 APOLLO...

Continue reading

XWELL, Inc. Reports Third Quarter 2024 Results

Written by Customer Service on . Posted in Public Companies.

NEW YORK, Nov. 14, 2024 (GLOBE NEWSWIRE) — XWELL, Inc. (Nasdaq: XWEL) (“XWELL” or the “Company”), an authority in wellness solutions for people on the go, today reported results for the third quarter and nine-month period ended September 30, 2024. Recent Highlights:XWELL delivered 2024 third quarter revenue growth of approximately 13% from the comparable quarter in 2023. Additionally, for the nine-month period ended September 30, 2024, XWELL delivered revenue growth of approximately 16% from the comparable nine-month period in 2023. XWELL continues to focus on reducing its cost structure and returning to profitability. For the nine-month period ended September 30, 2024, the Company:Reduced cost of sales by approximately 6% when compared with the comparable nine-month period in 2023. Reduced general and...

Continue reading

Xtreme One Entertainment Announces Third Quarter 2024 Financial Results

Written by Customer Service on . Posted in Public Companies.

Continued Investment in the Production and Distribution of XFC Live Events Yield Progress Towards Long-Term Strategic Growth Plan DETROIT, Nov. 14, 2024 (GLOBE NEWSWIRE) — Xtreme One Entertainment, Inc. (OTCPink: XONI) (the “Company” or “Xtreme One”) today announced its financial results for the third quarter ending September 30, 2024, details of which have been filed within the Company’s quarterly disclosure statement accessible at https://www.otcmarkets.com/stock/XONI/disclosure. “The team put on another incredible event this quarter with XFC 51: Evolution in Milwaukee. The more events we get under our belt, the more successful they become, and it allows us to further focus on amping up the production quality and fan engagement. As we move forward on our path, we continue to drive efficiencies that allow us to lower our per event...

Continue reading

FSI ANNOUNCES THIRD QUARTER, 2024 FINANCIAL RESULTS

Written by Customer Service on . Posted in Public Companies.

A Conference call is scheduled for Friday November 15th, 2024, 11:00am Eastern Time See dial in number below VICTORIA, BRITISH COLUMBIA, Nov. 14, 2024 (GLOBE NEWSWIRE) — FLEXIBLE SOLUTIONS INTERNATIONAL, INC. (NYSE Amex: FSI), is the developer and manufacturer of biodegradable polymers for oil extraction, detergent ingredients and water treatment as well as crop nutrient availability chemistry. Flexible Solutions also manufactures biodegradable and environmentally safe water and energy conservation technologies. Today the Company announces financial results for third quarter ended September 30, 2024. Mr. Daniel B. O’Brien, CEO, states, “This was another very good quarter and a significant recovery from the year earlier period.” Mr. O’Brien continues, “In addition to the improvement in our existing business, we believe we advanced...

Continue reading

Benitec Biopharma Releases First Quarter 2025 Financial Results and Provides Operational Update

Written by Customer Service on . Posted in Public Companies.

-Positive 270-day Interim Clinical Study Data for the First Subject and Positive 180-day Interim Clinical Study Data for the Second Subject Treated with the Low-Dose of BB-301 in the Phase 1b/2a Clinical Treatment Study Reported in October as a Late-Breaking Oral Presentation at the 29th Annual Congress of the World Muscle Society- -Third Subject Safely Treated with the Low-Dose of BB-301 in October 2024, and Fourth Subject Expected to Receive Treatment with the Low-Dose of BB-301 in December 2024 HAYWARD, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) — Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary “Silence and Replace” DNA-directed RNA interference (“ddRNAi”) platform, today announced financial...

Continue reading

Exagen Inc. Completes Validation and Regulatory Submission for New Lupus and Rheumatoid Arthritis Biomarkers on the AVISE® CTD Platform

Written by Customer Service on . Posted in Public Companies.

Significant enhancements will equip clinicians with even more diagnostic clarity in the treatment of patients with autoimmune disease CARLSBAD, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) — Exagen Inc., a leading provider of autoimmune testing, today announced the validation and regulatory submission for approval of new Systemic Lupus Erythematosus (SLE) and rheumatoid arthritis (RA) biomarkers, to be incorporated into the AVISE CTD platform. Collectively, these new biomarkers will further improve the clinical utility of AVISE CTD, providing clinicians with the information they need to definitively diagnose patients and shorten their autoimmune diagnostic journeys. Since 2012, AVISE CTD has delivered diagnostic clarity where overlapping clinical symptoms and ambiguous disease states make it difficult to arrive at a differential diagnosis...

Continue reading

Jewett-Cameron to Report Fiscal 2024 Full Year and Fourth Quarter Operational and Financial Results on November 20, 2024

Written by Customer Service on . Posted in Public Companies.

NORTH PLAINS, Ore., Nov. 14, 2024 (GLOBE NEWSWIRE) — Jewett-Cameron Trading Company Ltd. (“Jewett-Cameron”) (Nasdaq: JCTC), a company committed to innovative products that enrich outdoor spaces, will report its operational and financial results for its fiscal 2024 full year and fourth quarter, after the market close on Wednesday, November 20, 2024. The Company has scheduled a conference call and webcast that same day, Wednesday, November 20, 2024, at 4:30 p.m. Eastern time, to review the results followed by a question and answer session. Conference Call Details Date and Time: Wednesday, November 20, 2024, at 4:30 p.m. Eastern time Call-in Information: Interested parties can access the conference call by dialing (844) 836-8745 for United States callers or +1 (412) 317-6797. Webcast Information: The webcast will be accessible live...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.